Moomoo AI 已提取核心信息
TransCode Therapeutics, Inc. reported a preliminary cash balance of approximately $2.8 million as of December 31, 2023. This figure is subject to the completion of financial statements and may be adjusted upon finalization. The company's independent accounting firm has not provided any form of assurance on this estimate. Additionally, TransCode announced a 1-for-40 reverse stock split effective January 16, 2024, which is expected to help the company meet Nasdaq's minimum bid price requirement for continued listing. The reverse split will reduce the number of outstanding shares and adjust the exercise prices of stock options and warrants accordingly. Stockholders will not receive fractional shares; instead, they will be rounded up to the nearest whole number. The company's CUSIP number will change to 89357L 303 following...Show More
TransCode Therapeutics, Inc. reported a preliminary cash balance of approximately $2.8 million as of December 31, 2023. This figure is subject to the completion of financial statements and may be adjusted upon finalization. The company's independent accounting firm has not provided any form of assurance on this estimate. Additionally, TransCode announced a 1-for-40 reverse stock split effective January 16, 2024, which is expected to help the company meet Nasdaq's minimum bid price requirement for continued listing. The reverse split will reduce the number of outstanding shares and adjust the exercise prices of stock options and warrants accordingly. Stockholders will not receive fractional shares; instead, they will be rounded up to the nearest whole number. The company's CUSIP number will change to 89357L 303 following the reverse split. In executive movements, Robert Michael Dudley resigned as President, CEO, and director effective January 13, 2024, with Thomas A. Fitzgerald stepping in as Interim President and CEO while continuing his role as CFO. The company's stockholders had previously granted the Board the discretion to effect the reverse split at a ratio between 1-for-10 and 1-for-40, which was decided and announced on January 11, 2024.
TransCode Therapeutics, Inc.报告称，截至2023年12月31日，初步现金余额约为280万美元。这一数字视财务报表的完成情况而定，并可能在最后确定后进行调整。该公司的独立会计师事务所没有对这一估计提供任何形式的保证。此外，TransCode宣布自2024年1月16日起实行1比40的反向股票拆分，预计这将有助于该公司满足纳斯达克对继续上市的最低出价要求。反向拆分将减少已发行股票的数量，并相应地调整股票期权和认股权证的行使价格。股东不会获得部分股票；相反，股东将四舍五入到最接近的整数。反向拆分后，该公司的CUSIP号码将更改为89357L 303。在高管变动方面，罗伯特·...展开全部
TransCode Therapeutics, Inc.报告称，截至2023年12月31日，初步现金余额约为280万美元。这一数字视财务报表的完成情况而定，并可能在最后确定后进行调整。该公司的独立会计师事务所没有对这一估计提供任何形式的保证。此外，TransCode宣布自2024年1月16日起实行1比40的反向股票拆分，预计这将有助于该公司满足纳斯达克对继续上市的最低出价要求。反向拆分将减少已发行股票的数量，并相应地调整股票期权和认股权证的行使价格。股东不会获得部分股票；相反，股东将四舍五入到最接近的整数。反向拆分后，该公司的CUSIP号码将更改为89357L 303。在高管变动方面，罗伯特·迈克尔·达德利辞去了总裁、首席执行官和董事的职务，自2024年1月13日起生效，托马斯·菲茨杰拉德出任临时总裁兼首席执行官，同时继续担任首席财务官。该公司的股东此前曾授予董事会以1比10和1比40的比例进行反向拆分的自由裁量权，该比例是在2024年1月11日决定并宣布的。
有用
没用